Exelixis
EXEL
#1694
Rank
ยฃ8.96 B
Marketcap
ยฃ33.30
Share price
-0.02%
Change (1 day)
17.89%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2025 (TTM): ยฃ0.66 Billion

According to Exelixis's latest financial reports the company's current earnings are ยฃ2.28 Billion. In 2024 the company made an earning of ยฃ0.51 Billion, an increase over its 2023 earnings that were of ยฃ0.19 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) ยฃ0.66 B29.38%
2024 ยฃ0.51 B164.69%
2023 ยฃ0.19 B9.89%
2022 ยฃ0.17 B-20.33%
2021 ยฃ0.22 B124.82%
2020 ยฃ98.21 M-67.14%
2019 ยฃ0.29 B-11.94%
2018 ยฃ0.33 B185.09%
2017 ยฃ0.11 B-325.82%
2016 -ยฃ52.72 Million-58.12%
2015 -ยฃ0.13 Billion-37.61%
2014 -ยฃ0.21 Billion9.75%
2013 -ยฃ0.19 Billion65.96%
2012 -ยฃ0.12 Billion-291.63%
2011 ยฃ57.79 M-195.59%
2010 -ยฃ60.46 Million-42.17%
2009 -ยฃ0.11 Billion-18.98%
2008 -ยฃ0.13 Billion-6.99%
2007 -ยฃ0.14 Billion46.3%
2006 -ยฃ94.84 Million33.25%
2005 -ยฃ71.17 Million-30.92%
2004 -ยฃ0.11 Billion44.29%
2003 -ยฃ71.41 Million12.86%
2002 -ยฃ63.27 Million22.79%
2001 -ยฃ51.53 Million60.14%
2000 -ยฃ32.18 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
GlaxoSmithKline
GSK
ยฃ6.99 B 967.56%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
ยฃ6.83 B 942.07%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
ยฃ17.33 B 2,544.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ6.02 B 819.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
ยฃ6.18 B 844.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
ยฃ24.31 B 3,609.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ8.89 B 1,257.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-ยฃ24.44 Million-103.73%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-ยฃ21.8 Million-103.33%๐Ÿ‡บ๐Ÿ‡ธ USA